Barclays PLC Red Hill Biopharma Ltd. Transaction History

Barclays PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.63 - $2.58 $16,065 - $65,790	-25,500 Reduced 33.33%	51,000 $44,000
Q4 2021 Feb 14, 2022	BUY	$2.31 - $5.85 $176,696 - $447,478	76,492 Added 956150.0%	76,500 $197,000
Q3 2021 Nov 09, 2021	SELL	$4.55 - $10.36 $354 - $808	-78 Reduced 90.7%	8 $0
Q2 2021 Aug 13, 2021	SELL	$5.98 - $7.51 $233 - $292	-39 Reduced 31.2%	86 $1,000
Q1 2021 May 13, 2021	BUY	$6.98 - $11.29 $174 - $282	25 Added 25.0%	125 $1,000
Q4 2020 Feb 11, 2021	BUY	$7.81 - $10.39 $781 - $1,039	100 New	100 $1,000
Q2 2020 Aug 12, 2020	SELL	$4.6 - $8.6 $51,519 - $96,320	-11,200 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$3.51 - $6.17 $39,312 - $69,104	11,200 New	11,200 $51,000

40.4K

Ticker RDHL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 63,823,500
Market Cap $465M
Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.